Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1

作者：

Mammadzadeh, Aytaj ^{[1
]}

Peng, Fulei ^{[2
]}

Atrash, Shebli ^{[3
,4
]}

Hashmi, Hamza ^{[3
,5
]}

Mohan, Meera ^{[3
,6
]}

Alkharabsheh, Omar ^{[3
,7
]}

Afrough, Aimaz ^{[3
,8
]}

Cui, Wei ^{[3
,9
]}

Mahmoudjafari, Zahra ^{[3
,10
]}

Abdallah, Al-Ola ^{[11
,12
]}

机构：

[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan

[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA

[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA

[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA

[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4277 / 4278

页数：2

共 50 条

[21] B-Cell Maturation Antigen (BCMA) as a Biomarker for Assessing Multiple Myeloma Progression and Relapse
Joshi, Hemant
Wolters, Emily
Firpo-Betancourt, Adolfo
Mendu, Damodara Rao
LABORATORY INVESTIGATION, 2024, 104 (03) : S1424 - S1425
[22] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[23] B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
Sanchez, Larysa
Dardac, Alexandra
Madduri, Deepu
Richard, Shambavi
Richter, Joshua
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[24] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
Touzeau, Cyrille
Krishnan, Amrita Y.
Moreau, Philippe
Perrot, Aurore
Usmani, Saad Zafar
Manier, Salomon
Cavo, Michele
Martinez-Chamorro, Carmen
Nooka, Ajay K.
Martin, Thomas G.
Karlin, Lionel
Leleu, Xavier
Bahlis, Nizar J.
Besemer, Britta
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Kobos, Rachel
Garfall, Alfred L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Mohammed, Turab
Peres, Lauren
Colinleitzinger, Christelle
Puglianini, Omar Castaneda
Oswald, Laura
De Avila, Gabe
Grajales-Cruz, Ariel
Blue, Brandon
Ochoa-Bayona, Jose
Khimani, Farhad
Faramand, Rawan
Elmariah, Hany
Lazaryan, Aleksandr
Jain, Michael
Liu, Hein
Nishihori, Taiga
Shain, Ken
Baz, Rachid
Alsina, Melissa
Locke, Frederick
Freeman, Ciara
Hansen, Doris
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S473 - S474
[26] Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Mailankody, Sham
Jakubowiak, Andrzej J.
Htut, Myo
Costa, Luciano J.
Lee, Kelvin
Ganguly, Siddhartha
Kaufman, Jonathan L.
Siegel, David Samuel DiCapua
Bensinger, William
Cota, Mariana
Doerr, Thomas
DeVries, Todd
Wong, Sandy Wai Kuan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Therapy for Patients with relapsed and/or refractory multiple Myeloma New Data on BCMA-directed therapeutic Approaches
Rudesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 212 - 212
[28] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Polepally, Akshanth R.
Biesdorf, Carla
Uddin, Muhammad Erfan
Boehm, Nils
Ross, Jeremy A.
Kumar, Shaji Kunnathu
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Bueno, Orlando
Talati, Chetasi
Menon, Rajeev M.
BLOOD, 2023, 142
[29] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
Fang, Jiamin
Zhou, Fuling
ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083
[30] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
Arora, Sankalp
Giri, Smith
Godby, Kelly Nicole
Ravi, Gayathri
Costa, Luciano J.
Bal, Susan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →